Otsuka Holdings Co (OTSKY) 23.5700 $OTSKY
Equity Market Movement at a Glance -- Analyst Research on Compass Biotechnologies, Liquidmetal Technologies, Otsuka Holdings and Enel
ACCESSWIRE - Thu Mar 10, 9:15AM CST
NEW YORK, NY / ACCESSWIRE / March 10, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Compass Biotechnologies Inc. (OTC: COBI), Liquidmetal Technologies Inc. (OTC: LQMT), Otsuka Holdings Co. Ltd. (OTC: OTSKY) and Enel SpA (OTC: ENLAY). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
Atherosclerosis Pipeline: H2 2015 World Market Research Report
PR Newswire - Wed Mar 09, 6:30AM CST
Market research report titled "Atherosclerosis - Pipeline Review, H2 2015" provides an overview of the Atherosclerosis's therapeutic pipeline and enhances decision making capabilities to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
JNJ: 120.47 (-1.84), VCEL: 2.15 (-0.01), KNMD: (), OPK: 10.04 (-0.04), GILD: 79.56 (-0.09), MRK: 63.01 (-0.31), AZN: 33.58 (+0.14), OMER: 11.31 (-0.20)
Bladder Pain Global Clinical Trials Review, H2, 2015 - Key Companies are Aquinox Pharmaceuticals, Otsuka Holdings Co & CMX Research Inc. - Research and Markets
BusinessWire - Tue Mar 08, 9:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/vrqjjm/bladder_pain) has announced the addition of the "Bladder Pain Global Clinical Trials Review, H2, 2015" report to their offering.
Tuberculosis Therapeutics Development Pipeline Review, H2 2015 Featuring 60 Key Companies
M2 - Fri Feb 05, 4:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/b2fbvp/tuberculosis) has announced the addition of the "Tuberculosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Tuberculosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tuberculosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Tuberculosis Overview - Therapeutics Development - Pipeline Products for Tuberculosis - Overview - Pipeline Products for Tuberculosis - Comparative Analysis - Tuberculosis - Therapeutics under Development by Companies - Tuberculosis - Therapeutics under Investigation by Universities/Institutes - Tuberculosis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Tuberculosis - Products under Development by Companies - Tuberculosis - Products under Investigation by Universities/Institutes - Tuberculosis - Companies Involved in Therapeutics Development - Abera Bioscience AB - Achillion Pharmaceuticals, Inc. - BioDiem Ltd - BioLingus AG - Biomar Microbial Technologies - Bioversys AG - Celgene Corporation - Cellceutix Corporation - Chongqing Zhifei Biological Products Co., Ltd. - Ensol Biosciences Inc. - EpiVax, Inc. - FIT Biotech Oy - GangaGen Inc. - GlaxoSmithKline Plc - Globeimmune, Inc. - Hsiri Therapeutics, LLC - Imaxio SA - Immunitor, Inc. - ImmunoBiology Limited - Immunovaccine, Inc. - Inovio Pharmaceuticals, Inc. - Johnson & Johnson - Lipotek Pty Ltd. - Microbion Corporation - Microbiotix, Inc. - NEARMEDIC PLUS, Ltd - Novartis AG - Okklo Life Sciences BV - Orchid Chemicals & Pharmaceuticals Ltd - Otsuka Holdings Co., Ltd. - Polymun Scientific Immunbiologische Forschung GmbH - Prokarium Limited - QureTech Bio AB - Sanofi - Vichem Chemie Research Ltd. For more information visit http://www.researchandmarkets.com/research/b2...berculosis
JNJ: 120.47 (-1.84), INO: 8.82 (-0.06), ACHN: 8.81 (-0.05), GSK: 44.38 (-0.02), NVS: 81.90 (-0.44), CELGZ: 1.23 (+0.01)
Salivary Gland Cancer Pipeline Review, H2 2015
M2 - Fri Feb 05, 4:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/svqqnl/salivary_gland) has announced the addition of the "Salivary Gland Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Salivary Gland Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Salivary Gland Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Salivary Gland Cancer Overview - Therapeutics Development - Pipeline Products for Salivary Gland Cancer - Overview - Pipeline Products for Salivary Gland Cancer - Comparative Analysis - Salivary Gland Cancer - Therapeutics under Development by Companies - Salivary Gland Cancer - Therapeutics under Investigation by Universities/Institutes - Salivary Gland Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Salivary Gland Cancer - Products under Development by Companies - Salivary Gland Cancer - Products under Investigation by Universities/Institutes - Salivary Gland Cancer - Companies Involved in Therapeutics Development - AstraZeneca Plc - Bayer AG - Ignyta, Inc. - Loxo Oncology, Inc. - Otsuka Holdings Co., Ltd. - Plexxikon Inc. For more information visit http://www.researchandmarkets.com/research/sv...vary_gland
LOXO: 26.34 (-0.55), RXDX: 5.56 (-0.09), AZN: 33.58 (+0.14)
Endometrial Cancer - Pipeline Review, H2 2015
M2 - Tue Feb 02, 5:46AM CST
Research and Markets (http://www.researchandmarkets.com/research/s66589/endometrial) has announced the addition of the "Endometrial Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Endometrial Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endometrial Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Endometrial Cancer Overview - Therapeutics Development - Pipeline Products for Endometrial Cancer - Overview - Pipeline Products for Endometrial Cancer - Comparative Analysis - Endometrial Cancer - Therapeutics under Development by Companies - Endometrial Cancer - Therapeutics under Investigation by Universities/Institutes - Endometrial Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Endometrial Cancer - Products under Development by Companies - Endometrial Cancer - Products under Investigation by Universities/Institutes - Endometrial Cancer - Companies Involved in Therapeutics Development - Ability Pharma, SL - Acceleron Pharma, Inc. - Advenchen Laboratories, LLC - Aeterna Zentaris Inc. - Arno Therapeutics, Inc. - ArQule, Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - BeiGene(Beijing) Co.,Ltd - Boehringer Ingelheim GmbH - Cellceutix Corporation - Critical Outcome Technologies Inc. - Eisai Co., Ltd. - Eli Lilly and Company - Esperance Pharmaceuticals, Inc. - Exelixis, Inc. - Galena Biopharma, Inc. - Genmab A/S - GlaxoSmithKline Plc - Gradalis Inc. - ImmunoGen, Inc. - Incyte Corporation - Karyopharm Therapeutics, Inc. - Medivation, Inc. - Merck & Co., Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. - Novartis AG - OncoHoldings, Inc. - Oncothyreon Inc. - Otsuka Holdings Co., Ltd. - Pharma Mar, S.A. - Pharmsynthez - Puma Biotechnology, Inc. - Sanofi For more information visit http://www.researchandmarkets.com/research/s6...ndometrial
INCY: 78.45 (-2.10), IMGN: 3.09 (-0.13), ARQL: 1.45 (-0.05), LLY: 80.02 (-0.24), GSK: 44.38 (-0.02), ONTY: 1.21 (+0.02), MDVN: 65.17 (-0.13), MRK: 63.01 (-0.31), AZN: 33.58 (+0.14), AVEO: 0.97 (-0.03), GALE: 0.41 (-0.01), PBYI: 48.50 (-0.39), NVS: 81.90 (-0.44), KPTI: 7.26 (+0.04), XLRN: 30.00 (-0.15), EXEL: 10.59 (-0.17)
Bipolar Disorder (Manic Depression) - Pipeline Review
M2 - Mon Feb 01, 4:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/f9ppsp/bipolar_disorder) has announced the addition of the "Bipolar Disorder (Manic Depression) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Bipolar Disorder (Manic Depression), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bipolar Disorder (Manic Depression) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Bipolar Disorder (Manic Depression) Overview - Therapeutics Development - Pipeline Products for Bipolar Disorder (Manic Depression) - Overview - Pipeline Products for Bipolar Disorder (Manic Depression) - Comparative Analysis - Bipolar Disorder (Manic Depression) - Therapeutics under Development by Companies - Bipolar Disorder (Manic Depression) - Therapeutics under Investigation by Universities/Institutes - Bipolar Disorder (Manic Depression) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Bipolar Disorder (Manic Depression) - Products under Development by Companies - Bipolar Disorder (Manic Depression) - Products under Investigation by Universities/Institutes - Bipolar Disorder (Manic Depression) - Companies Involved in Therapeutics Development Companies Mentioned: - Aequus Pharmaceuticals Inc. - ANP Technologies, Inc. - AstraZeneca Plc - Convergence Pharmaceuticals Ltd. - D-Pharm Ltd. - Delpor, Inc. - Intas Pharmaceuticals Ltd. - Intra-Cellular Therapies, Inc. - Johnson & Johnson - KemPharm, Inc. - Neurocrine Biosciences, Inc. - Omeros Corporation - Otsuka Holdings Co., Ltd. - Pfizer Inc. - Reviva Pharmaceuticals Inc. - SK Biopharmaceuticals Co., Ltd. - Sumitomo Dainippon Pharma Co., Ltd. - Teva Pharmaceutical Industries Limited - Zogenix, Inc. - Zysis Limited For more information visit http://www.researchandmarkets.com/research/f9...r_disorder
JNJ: 120.47 (-1.84), NBIX: 48.46 (-0.27), KMPH: 4.69 (+0.38), ZGNX: 9.83 (+0.16), PFE: 34.91 (-0.20), AZN: 33.58 (+0.14), TEVA: 53.78 (-0.76), ITCI: 41.11 (+0.10), OMER: 11.31 (-0.20)
Migraine Therapeutic Development Pipeline Review, H2 2015
M2 - Thu Jan 28, 4:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/tw7v3m/migraine) has announced the addition of the "Migraine - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Migraine, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Migraine and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Migraine Overview - Therapeutics Development - Pipeline Products for Migraine - Overview - Pipeline Products for Migraine - Comparative Analysis - Migraine - Therapeutics under Development by Companies - Migraine - Therapeutics under Investigation by Universities/Institutes - Migraine - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Migraine - Products under Development by Companies - Migraine - Products under Investigation by Universities/Institutes - Migraine - Companies Involved in Therapeutics Development - Ache Laboratorios Farmaceuticos S/A - Acorda Therapeutics, Inc. - Afferent Pharmaceuticals, Inc. - Alder Biopharmaceuticals Inc. - Allergan Plc - Amgen Inc. - Astellas Pharma Inc. - BioDelivery Sciences International, Inc. - Biofrontera AG - Charleston Laboratories, Inc. - CoLucid Pharmaceuticals, Inc. - Corium International, Inc. - D-Pharm Ltd. - Eli Lilly and Company - iCeutica, Inc. - Impel NeuroPharma, Inc. - Mallinckrodt Plc - Medestea Research & Production S.p.A. - Merck & Co., Inc. - Monosol Rx, LLC - NAL Pharmaceuticals Ltd. - Nektar Therapeutics - Noxxon Pharma AG - Otsuka Holdings Co., Ltd. - Pantarhei Bioscience BV - Pivot Pharmaceuticals Inc - Pozen, Inc. - Promius Pharma, LLC - RedHill Biopharma Ltd. - Revance Therapeutics, Inc. - Shin Nippon Biomedical Laboratories, Ltd. - Suda Ltd - Teva Pharmaceutical Industries Limited - TheraJect, Inc. - Trevena, Inc. - Trigemina, Inc. - Vertex Pharmaceuticals Incorporated - Zosano Pharma Corporation For more information visit http://www.researchandmarkets.com/research/tw7v3m/migraine
BDSI: 2.84 (-0.04), TRVN: 7.35 (+0.04), VRTX: 100.03 (-2.45), RDHL: 15.35 (-0.02), ZSAN: 1.32 (unch), AMGN: 172.50 (-2.08), LLY: 80.02 (-0.24), ACOR: 24.06 (-0.20), NKTR: 17.56 (-0.08), AGN: 253.93 (-0.12), CORI: 4.43 (+0.03), ALDR: 30.44 (-0.80), CLCD: 8.75 (-0.02), MRK: 63.01 (-0.31), TEVA: 53.78 (-0.76), RVNC: 15.50 (+0.50), POZN: 5.94 (-0.43)
Traders Look to Upside - Analyst Research on Nintendo, Experian, Otsuka Holdings and Terna Rete Elettrica Nazionale
ACCESSWIRE - Fri Jan 22, 8:10AM CST
NEW YORK, NY / ACCESSWIRE / January 22, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Nintendo Co. Ltd. (OTC: NTDOY), Experian PLC (OTC: EXPGY), Otsuka Holdings Co. Ltd. (OTC: OTSKY) and Terna Rete Elettrica Nazionale SPA (OTC: TEZNY). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2015
M2 - Thu Jan 14, 5:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/z9cx7q/chronic_kidney) has announced the addition of the "Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2015" report to their offering. The report Chronic Kidney Disease (Chronic Renal Failure) provides an overview of its therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic Kidney Disease (Chronic Renal Failure) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic Kidney Disease (Chronic Renal Failure) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Acceleron Pharma, Inc. - Angion Biomedica Corp. - Apceth GmbH & Co. KG - Astellas Pharma Inc. - Bayer AG - Bio-inRen - Boryung Pharmaceutical Co., Ltd. - Complexa, Inc. - Eli Lilly and Company - Evotec AG - Intercept Pharmaceuticals, Inc. - Isis Pharmaceuticals, Inc. - La Jolla Pharmaceutical Company - Lupin Limited - Nippon Zoki Pharmaceutical Co., Ltd. - OPKO Health, Inc. - Otsuka Holdings Co., Ltd. - Prismic Pharmaceuticals, Inc. - Prolong Pharmaceuticals - ProMetic Life Sciences Inc. - Reata Pharmaceuticals, Inc. - Red Glead Discovery AB - RegenMedTX, LLC - Resverlogix Corp. - Sphaera Pharma Pvt. Ltd. - Stelic Institute & Co. - Thrasos Therapeutics Inc. - Toray Industries, Inc. - VBS Pharmaceuticals - Vicore Pharma AB For more information visit http://www.researchandmarkets.com/research/z9...nic_kidney
LLY: 80.02 (-0.24), ISIS: 57.56 (-0.28), OPK: 10.04 (-0.04), ICPT: 165.48 (+0.43), XLRN: 30.00 (-0.15)
Global Treatment Resistant Depression Therapeutics Pipeline Review, H2 2015
M2 - Wed Jan 06, 8:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/qczdjq/treatment) has announced the addition of the "Treatment Resistant Depression - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Treatment Resistant Depression, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Treatment Resistant Depression and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Report Coverage - Treatment Resistant Depression Overview - Therapeutics Development - Pipeline Products for Treatment Resistant Depression - Overview - Pipeline Products for Treatment Resistant Depression - Comparative Analysis - Treatment Resistant Depression - Therapeutics under Development by Companies - Treatment Resistant Depression - Therapeutics under Investigation by Universities/Institutes - Treatment Resistant Depression - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Treatment Resistant Depression - Products under Development by Companies - Treatment Resistant Depression - Products under Investigation by Universities/Institutes - Treatment Resistant Depression - Companies Involved in Therapeutics Development - Addex Therapeutics Ltd - Amorsa Therapeutics Inc. - F. Hoffmann-La Roche Ltd. - Johnson & Johnson - Otsuka Holdings Co., Ltd. For more information visit http://www.researchandmarkets.com/research/qczdjq/treatment
JNJ: 120.47 (-1.84)
Nocturia Global Clinical Trials Review, H2, 2015 - Analysis, Technologies & Forecasts
M2 - Tue Dec 29, 11:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/q32p5v/nocturia_global) has announced the addition of the "Nocturia Global Clinical Trials Review, H2, 2015" report to their offering. The clinical trial report, Nocturia Global Clinical Trials Review, H2, 2015" provides an overview of Nocturia clinical trials scenario. This report provides top line data relating to the clinical trials on Nocturia. The eport includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. It also provides prominent drugs for in-progress trials (based on number of ongoing trials). Key Topics Covered: - The report provides a snapshot of the global clinical trials landscape - Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status - The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company - The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment - The Report provides enrollment trends for the past five years - Report provides latest news for the past three months Benefits of this Report: - Assists in formulating key business strategies with regards to investment - Helps in identifying prominent locations for conducting clinical trials which saves time and cost - Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities - Supports understanding of trials count and enrollment trends by country in global therapeutics market - Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials - Facilitates clinical trial assessment of the indication on a global, regional and country level Companies Mentioned: - Ferring International Center S.A. - Vantia Limited - Serenity Pharmaceuticals Corporation - OBN (UK) Ltd. - Accelovance Inc. - Astellas Pharma Inc. - Allergan Plc - Otsuka Holdings Co., Ltd. - Axis Clinical Trials For more information visit http://www.researchandmarkets.com/research/q3...ria_global
AGN: 253.93 (-0.12)
Polycystic Kidney Disease Global Clinical Trials Review, H2, 2015 - Analysis, Technologies & Forecasts
M2 - Tue Dec 29, 8:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/lj4h24/polycystic_kidney) has announced the addition of the "Polycystic Kidney Disease Global Clinical Trials Review, H2, 2015" report to their offering. The clinical trial report, Polycystic Kidney Disease Global Clinical Trials Review, H2, 2015" provides an overview of Polycystic Kidney Disease clinical trials scenario. This report provides top line data relating to the clinical trials on Polycystic Kidney Disease. The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. It also provides prominent drugs for in-progress trials (based on number of ongoing trials). Key Topics Covered: - The report provides a snapshot of the global clinical trials landscape - Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status - The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company - The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment Benefits of this Report: - Assists in formulating key business strategies with regards to investment - Helps in identifying prominent locations for conducting clinical trials which saves time and cost - Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities - Supports understanding of trials count and enrollment trends by country in global therapeutics market - Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials - Facilitates clinical trial assessment of the indication on a global, regional and country level Companies Mentioned: - Otsuka Holdings Co., Ltd. - Pfizer Inc. - Ipsen S.A. - Novartis AG - Kadmon Corporation, LLC - Merck & Co., Inc. - Daiichi Sankyo Company, Limited - Diablo Clinical Research, Inc. - C. H. Boehringer Sohn AG & Co. KG - Boehringer Ingelheim Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/lj...tic_kidney
PFE: 34.91 (-0.20), MRK: 63.01 (-0.31), NVS: 81.90 (-0.44)
Major Depressive Disorder - Pipeline Review, H2 2015
M2 - Thu Dec 17, 2:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/496zq2/major_depressive) has announced the addition of the "Major Depressive Disorder - Pipeline Review, H2 2015" report to their offering. The report provides an overview of the Major Depressive Disorder's therapeutic pipeline. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to Buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Major Depressive Disorder - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Major Depressive Disorder pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Aequus Pharmaceuticals Inc. - Alkermes Plc - Allergan Plc - Angelini Group - Azevan Pharmaceuticals, Inc. - BioCrea GmbH - Bristol-Myers Squibb Company - Cerecor Inc. - e-Therapeutics Plc - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - H. Lundbeck A/S - Hua Medicine Ltd. - Intra-Cellular Therapies, Inc. - Jiangsu Hansoh Pharmaceutical Co., Ltd. - Johnson & Johnson - Lead Discovery Center GmbH - Luye Pharma Group Ltd. - Mapreg S.A.S. - Methylation Sciences Inc. - miCure Therapeutics Ltd. - Mitsubishi Tanabe Pharma Corporation - Naurex, Inc. - Neuralstem, Inc. - nLife Therapeutics, S.L. - Otsuka Holdings Co., Ltd. - Pherin Pharmaceuticals, Inc. - Reviva Pharmaceuticals Inc. - Richter Gedeon Nyrt. - Saniona AB - Sumitomo Dainippon Pharma Co., Ltd. - Sunovion Pharmaceuticals Inc. - Suven Life Sciences Ltd. - VistaGen Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/49...depressive
LLY: 80.02 (-0.24), BMY: 59.54 (-0.49), GSK: 44.38 (-0.02), ALKS: 47.03 (-1.00), AGN: 253.93 (-0.12), CERCU: 5.03 (-0.56), JNJ: 120.47 (-1.84), ITCI: 41.11 (+0.10), CUR: 0.27 (+0.06)
Global Refractory Acute Myeloid Leukemia Therapeutics Pipeline Review, H2 2015 - 50 Companies & 117 Drug Profiles
M2 - Mon Dec 14, 10:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/5gtx2j/refractory_acute) has announced the addition of the "Refractory Acute Myeloid Leukemia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Refractory Acute Myeloid Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Acute Myeloid Leukemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 4SC AG - AbbVie Inc. - Actinium Pharmaceuticals, Inc. - Agios Pharmaceuticals, Inc. - Amgen Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - BioLineRx, Ltd. - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - Calithera Biosciences, Inc. - Celgene Corporation - Cornerstone Pharmaceuticals, Inc. - CTI BioPharma Corp. - Daiichi Sankyo Company, Limited - Eisai Co., Ltd. - EpiZyme, Inc. - GlaxoSmithKline Plc - Jiangsu Hansoh Pharmaceutical Co., Ltd. - JW Pharmaceutical Corporation - Karyopharm Therapeutics, Inc. - Kyowa Hakko Kirin Co., Ltd. - Les Laboratoires Servier SAS - MacroGenics, Inc. - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - NantKwest, Inc. - Novartis AG - Otsuka Holdings Co., Ltd. - Oxford BioTherapeutics Ltd - Synta Pharmaceuticals Corp. - TaiGen Biotechnology Co., Ltd. - Threshold Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/5g...tory_acute
MGNX: 31.93 (+0.10), AMGN: 172.50 (-2.08), EPZM: 8.63 (-0.09), GSK: 44.38 (-0.02), BMY: 59.54 (-0.49), CTIC: 0.35 (unch), SNTA: 0.34 (+0.07), ATNM: 1.70 (-0.02), MRK: 63.01 (-0.31), AZN: 33.58 (+0.14), AVEO: 0.97 (-0.03), CALA: 3.12 (-0.16), ABBV: 66.83 (-0.56), AGIO: 41.30 (-0.33), NVS: 81.90 (-0.44), KPTI: 7.26 (+0.04), CELGZ: 1.23 (+0.01)
World Adenocarcinoma of the Gastroesophageal Junction Pipeline Review, H2 2015 - 28 Companies & 32 Drug Profiles
M2 - Mon Dec 14, 9:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/x93qtv/adenocarcinoma_of) has announced the addition of the "Adenocarcinoma of the Gastroesophageal Junction - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Adenocarcinoma Of The Gastroesophageal Junction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Adenocarcinoma Of The Gastroesophageal Junction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AB Science SA - Amgen Inc. - ArQule, Inc. - AstraZeneca Plc - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - Cerulean Pharma, Inc. - Daiichi Sankyo Company, Limited - Dr. Reddy's Laboratories Limited - Eli Lilly and Company - Epirus Biopharmaceuticals, Inc. - F. Hoffmann-La Roche Ltd. - Ganymed Pharmaceuticals AG - Genentech, Inc. - Gilead Sciences, Inc. - Imugene Limited - Johnson & Johnson - Mebiopharm Co., Ltd. - MedImmune, LLC - Merck & Co., Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. - Novartis AG - Oncobiologics, Inc. - Otsuka Holdings Co., Ltd. - Panacea Biotec Limited - Sanofi Drug Profiles - (tipiracil hydrochloride trifluridine) - alpelisib - AMG-337 - avelumab - AZD-4547 - BI-853520 - cabazitaxel - CRLX-101 - DS-8201a - durvalumab tremelimumab - emibetuzumab - erismodegib - GS-5745 - Her-VAXX - IMAB-362 - indusatumab vedotin - ipatasertib - ipilimumab - JNJ-42756493 - masitinib - MBP-426 - napabucasin - panitumumab - PDR-001 - pembrolizumab - pertuzumab - ramucirumab - SAR-408701 - solitomab - tivantinib - trastuzumab biosimilar - trastuzumab emtansine For more information visit http://www.researchandmarkets.com/research/x9...rcinoma_of
CERU: 2.86 (-0.02), ARQL: 1.45 (-0.05), AMGN: 172.50 (-2.08), LLY: 80.02 (-0.24), BMY: 59.54 (-0.49), JNJ: 120.47 (-1.84), GILD: 79.56 (-0.09), MRK: 63.01 (-0.31), AZN: 33.58 (+0.14), NVS: 81.90 (-0.44)
Mycobacterium Tuberculosis Infections Global Clinical Trials Review, H2, 2015 - Analysis, Technologies & Forecast
M2 - Mon Dec 14, 5:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/zcz4kq/mycobacterium) has announced the addition of the "Mycobacterium Tuberculosis Infections Global Clinical Trials Review, H2, 2015" report to their offering. The clinical trial report, Mycobacterium Tuberculosis Infections Global Clinical Trials Review, H2, 2015" provides an overview of Mycobacterium Tuberculosis Infections clinical trials scenario. This report provides top line data relating to the clinical trials on Mycobacterium Tuberculosis Infections. It includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using Our proprietary database - Pharma eTrack Clinical trials database. Key Topics Covered: - The report provides a snapshot of the global clinical trials landscape - Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status - The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company - The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment - The Report provides enrollment trends for the past five years Benefits of this Report: - Assists in formulating key business strategies with regards to investment - Helps in identifying prominent locations for conducting clinical trials which saves time and cost - Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities - Supports understanding of trials count and enrollment trends by country in global therapeutics market - Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials Companies Mentioned: - Johnson & Johnson - GlaxoSmithKline Plc - Pfizer Inc. - Sanofi - Macleods Pharmaceuticals Limited - Sequella, Inc. - Merck & Co., Inc. - Quintiles Transnational Holdings Inc. - Otsuka Holdings Co., Ltd. - Bandim Health Project For more information visit http://www.researchandmarkets.com/research/zc...obacterium
JNJ: 120.47 (-1.84), PFE: 34.91 (-0.20), MRK: 63.01 (-0.31), GSK: 44.38 (-0.02)
Dyskinesia Pipeline Review - H2 2015 Report
M2 - Thu Dec 10, 10:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/vmxv9t/dyskinesia) has announced the addition of the "Dyskinesia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Dyskinesia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dyskinesia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Adamas Pharmaceuticals, Inc. - Addex Therapeutics Ltd - Advicenne Pharma - Amarantus Bioscience Holdings, Inc. - Astraea Therapeutics, LLC - BioMarin Pharmaceutical Inc. - Catalyst Biosciences, Inc. - Catalyst Pharmaceutical Partners, Inc. - Cerecor Inc. - Contera Pharma ApS - EpiVax, Inc. - Heptares Therapeutics Limited - Hua Medicine Ltd. - Integrative Research Laboratories Sweden AB - Ipsen S.A. - Medy-Tox Inc. - Merz Pharmaceuticals GmbH - MitoDys Therapeutics Limited - Neurim Pharmaceuticals Ltd - Neurocrine Biosciences, Inc. - Neurolixis Inc. - Osmotica Pharmaceutical Corp. - Otsuka Holdings Co., Ltd. - Revance Therapeutics, Inc. - Santhera Pharmaceuticals Holding AG - SciFluor Life Sciences, LLC - Synchroneuron Inc. - Teva Pharmaceutical Industries Limited For more information visit http://www.researchandmarkets.com/research/vmxv9t/dyskinesia
CERCU: 5.03 (-0.56), NBIX: 48.46 (-0.27), BMRN: 90.97 (-2.14), CPRX: 0.76 (+0.01), CBIO: 1.34 (unch), TEVA: 53.77 (-0.77), RVNC: 15.50 (+0.50)
Dementia Therapeutics - H2 2015 Pipeline Review
M2 - Fri Dec 04, 4:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/lj5mlv/dementia) has announced the addition of the "Dementia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Dementia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dementia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Adamas Pharmaceuticals, Inc. - Addex Therapeutics Ltd - Alector LLC - AlzProtect SAS - Apceth GmbH & Co. KG - BioArctic Neuroscience AB - Biogen, Inc. - Biotie Therapies Corp. - Chase Pharmaceuticals Corporation - Chronos Therapeutics Limited - Daewoong Pharmaceutical Co., Ltd. - Eisai Co., Ltd. - FORUM Pharmaceuticals Inc. - H. Lundbeck A/S - Hyundai Pharmaceutical Co., Ltd. - Ildong Pharmaceutical Co., Ltd. - IMMD Inc. - ImStar Therapeutics Inc. - Integrative Research Laboratories Sweden AB - Intellect Neurosciences, Inc. - Intra-Cellular Therapies, Inc. - MediPost Co., Ltd. - Neurimmune Holding AG - Neurodyn Inc. - Neuropore Therapies, Inc. - Oryzon Genomics S.A. - Otsuka Holdings Co., Ltd. - Pacific Northwest Biotechnology, LLC - Pivot Pharmaceuticals Inc - ProteoTech, Inc. - Sinil Pharmaceutical Co., Ltd - SK Chemicals Co., Ltd. - Tautatis Incorporated - Varinel, Inc. - WhanIn Pharmaceutical Co., Ltd. For more information visit http://www.researchandmarkets.com/research/lj5mlv/dementia
ITCI: 41.11 (+0.10)
Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2015
M2 - Fri Dec 04, 4:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/dk2pfp/posttraumatic) has announced the addition of the "Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Post-Traumatic Stress Disorder (PTSD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post-Traumatic Stress Disorder (PTSD) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Addex Therapeutics Ltd - Azevan Pharmaceuticals, Inc. - Catalyst Pharmaceutical Partners, Inc. - Eli Lilly and Company - HolsboerMaschmeyer NeuroChemie GmbH - Humanetics Corporation - Intra-Cellular Therapies, Inc. - Marinus Pharmaceuticals, Inc. - Neuralstem, Inc. - Neurocrine Biosciences, Inc. - NeuroNascent, Inc. - Omeros Corporation - Otsuka Holdings Co., Ltd. - Pfizer Inc. - Polleo Pharma Limited - Synchroneuron Inc. - Tonix Pharmaceuticals Holding Corp. - Vanda Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/dk...ttraumatic
NBIX: 48.46 (-0.27), TNXP: 2.50 (unch), MRNS: 1.47 (-0.12), CPRX: 0.76 (+0.01), VNDA: 12.68 (unch), PFE: 34.91 (-0.20), ITCI: 41.11 (+0.10), LLY: 80.02 (-0.24), OMER: 11.31 (-0.20), CUR: 0.27 (+0.06)
Equity Market Movement at a Glance -- Analyst Research on Compass Biotechnologies, Liquidmetal Technologies, Otsuka Holdings and Enel
ACCESSWIRE - Thu Mar 10, 9:15AM CST
NEW YORK, NY / ACCESSWIRE / March 10, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Compass Biotechnologies Inc. (OTC: COBI), Liquidmetal Technologies Inc. (OTC: LQMT), Otsuka Holdings Co. Ltd. (OTC: OTSKY) and Enel SpA (OTC: ENLAY). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
Atherosclerosis Pipeline: H2 2015 World Market Research Report
PR Newswire - Wed Mar 09, 6:30AM CST
Market research report titled "Atherosclerosis - Pipeline Review, H2 2015" provides an overview of the Atherosclerosis's therapeutic pipeline and enhances decision making capabilities to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
JNJ: 120.47 (-1.84), VCEL: 2.15 (-0.01), KNMD: (), OPK: 10.04 (-0.04), GILD: 79.56 (-0.09), MRK: 63.01 (-0.31), AZN: 33.58 (+0.14), OMER: 11.31 (-0.20)
Bladder Pain Global Clinical Trials Review, H2, 2015 - Key Companies are Aquinox Pharmaceuticals, Otsuka Holdings Co & CMX Research Inc. - Research and Markets
BusinessWire - Tue Mar 08, 9:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/vrqjjm/bladder_pain) has announced the addition of the "Bladder Pain Global Clinical Trials Review, H2, 2015" report to their offering.
Tuberculosis Therapeutics Development Pipeline Review, H2 2015 Featuring 60 Key Companies
M2 - Fri Feb 05, 4:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/b2fbvp/tuberculosis) has announced the addition of the "Tuberculosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Tuberculosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tuberculosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Tuberculosis Overview - Therapeutics Development - Pipeline Products for Tuberculosis - Overview - Pipeline Products for Tuberculosis - Comparative Analysis - Tuberculosis - Therapeutics under Development by Companies - Tuberculosis - Therapeutics under Investigation by Universities/Institutes - Tuberculosis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Tuberculosis - Products under Development by Companies - Tuberculosis - Products under Investigation by Universities/Institutes - Tuberculosis - Companies Involved in Therapeutics Development - Abera Bioscience AB - Achillion Pharmaceuticals, Inc. - BioDiem Ltd - BioLingus AG - Biomar Microbial Technologies - Bioversys AG - Celgene Corporation - Cellceutix Corporation - Chongqing Zhifei Biological Products Co., Ltd. - Ensol Biosciences Inc. - EpiVax, Inc. - FIT Biotech Oy - GangaGen Inc. - GlaxoSmithKline Plc - Globeimmune, Inc. - Hsiri Therapeutics, LLC - Imaxio SA - Immunitor, Inc. - ImmunoBiology Limited - Immunovaccine, Inc. - Inovio Pharmaceuticals, Inc. - Johnson & Johnson - Lipotek Pty Ltd. - Microbion Corporation - Microbiotix, Inc. - NEARMEDIC PLUS, Ltd - Novartis AG - Okklo Life Sciences BV - Orchid Chemicals & Pharmaceuticals Ltd - Otsuka Holdings Co., Ltd. - Polymun Scientific Immunbiologische Forschung GmbH - Prokarium Limited - QureTech Bio AB - Sanofi - Vichem Chemie Research Ltd. For more information visit http://www.researchandmarkets.com/research/b2...berculosis
JNJ: 120.47 (-1.84), INO: 8.82 (-0.06), ACHN: 8.81 (-0.05), GSK: 44.38 (-0.02), NVS: 81.90 (-0.44), CELGZ: 1.23 (+0.01)
Salivary Gland Cancer Pipeline Review, H2 2015
M2 - Fri Feb 05, 4:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/svqqnl/salivary_gland) has announced the addition of the "Salivary Gland Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Salivary Gland Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Salivary Gland Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Salivary Gland Cancer Overview - Therapeutics Development - Pipeline Products for Salivary Gland Cancer - Overview - Pipeline Products for Salivary Gland Cancer - Comparative Analysis - Salivary Gland Cancer - Therapeutics under Development by Companies - Salivary Gland Cancer - Therapeutics under Investigation by Universities/Institutes - Salivary Gland Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Salivary Gland Cancer - Products under Development by Companies - Salivary Gland Cancer - Products under Investigation by Universities/Institutes - Salivary Gland Cancer - Companies Involved in Therapeutics Development - AstraZeneca Plc - Bayer AG - Ignyta, Inc. - Loxo Oncology, Inc. - Otsuka Holdings Co., Ltd. - Plexxikon Inc. For more information visit http://www.researchandmarkets.com/research/sv...vary_gland
LOXO: 26.34 (-0.55), RXDX: 5.56 (-0.09), AZN: 33.58 (+0.14)
Endometrial Cancer - Pipeline Review, H2 2015
M2 - Tue Feb 02, 5:46AM CST
Research and Markets (http://www.researchandmarkets.com/research/s66589/endometrial) has announced the addition of the "Endometrial Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Endometrial Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endometrial Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Endometrial Cancer Overview - Therapeutics Development - Pipeline Products for Endometrial Cancer - Overview - Pipeline Products for Endometrial Cancer - Comparative Analysis - Endometrial Cancer - Therapeutics under Development by Companies - Endometrial Cancer - Therapeutics under Investigation by Universities/Institutes - Endometrial Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Endometrial Cancer - Products under Development by Companies - Endometrial Cancer - Products under Investigation by Universities/Institutes - Endometrial Cancer - Companies Involved in Therapeutics Development - Ability Pharma, SL - Acceleron Pharma, Inc. - Advenchen Laboratories, LLC - Aeterna Zentaris Inc. - Arno Therapeutics, Inc. - ArQule, Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - BeiGene(Beijing) Co.,Ltd - Boehringer Ingelheim GmbH - Cellceutix Corporation - Critical Outcome Technologies Inc. - Eisai Co., Ltd. - Eli Lilly and Company - Esperance Pharmaceuticals, Inc. - Exelixis, Inc. - Galena Biopharma, Inc. - Genmab A/S - GlaxoSmithKline Plc - Gradalis Inc. - ImmunoGen, Inc. - Incyte Corporation - Karyopharm Therapeutics, Inc. - Medivation, Inc. - Merck & Co., Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. - Novartis AG - OncoHoldings, Inc. - Oncothyreon Inc. - Otsuka Holdings Co., Ltd. - Pharma Mar, S.A. - Pharmsynthez - Puma Biotechnology, Inc. - Sanofi For more information visit http://www.researchandmarkets.com/research/s6...ndometrial
INCY: 78.45 (-2.10), IMGN: 3.09 (-0.13), ARQL: 1.45 (-0.05), LLY: 80.02 (-0.24), GSK: 44.38 (-0.02), ONTY: 1.21 (+0.02), MDVN: 65.17 (-0.13), MRK: 63.01 (-0.31), AZN: 33.58 (+0.14), AVEO: 0.97 (-0.03), GALE: 0.41 (-0.01), PBYI: 48.50 (-0.39), NVS: 81.90 (-0.44), KPTI: 7.26 (+0.04), XLRN: 30.00 (-0.15), EXEL: 10.59 (-0.17)
Bipolar Disorder (Manic Depression) - Pipeline Review
M2 - Mon Feb 01, 4:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/f9ppsp/bipolar_disorder) has announced the addition of the "Bipolar Disorder (Manic Depression) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Bipolar Disorder (Manic Depression), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bipolar Disorder (Manic Depression) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Bipolar Disorder (Manic Depression) Overview - Therapeutics Development - Pipeline Products for Bipolar Disorder (Manic Depression) - Overview - Pipeline Products for Bipolar Disorder (Manic Depression) - Comparative Analysis - Bipolar Disorder (Manic Depression) - Therapeutics under Development by Companies - Bipolar Disorder (Manic Depression) - Therapeutics under Investigation by Universities/Institutes - Bipolar Disorder (Manic Depression) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Bipolar Disorder (Manic Depression) - Products under Development by Companies - Bipolar Disorder (Manic Depression) - Products under Investigation by Universities/Institutes - Bipolar Disorder (Manic Depression) - Companies Involved in Therapeutics Development Companies Mentioned: - Aequus Pharmaceuticals Inc. - ANP Technologies, Inc. - AstraZeneca Plc - Convergence Pharmaceuticals Ltd. - D-Pharm Ltd. - Delpor, Inc. - Intas Pharmaceuticals Ltd. - Intra-Cellular Therapies, Inc. - Johnson & Johnson - KemPharm, Inc. - Neurocrine Biosciences, Inc. - Omeros Corporation - Otsuka Holdings Co., Ltd. - Pfizer Inc. - Reviva Pharmaceuticals Inc. - SK Biopharmaceuticals Co., Ltd. - Sumitomo Dainippon Pharma Co., Ltd. - Teva Pharmaceutical Industries Limited - Zogenix, Inc. - Zysis Limited For more information visit http://www.researchandmarkets.com/research/f9...r_disorder
JNJ: 120.47 (-1.84), NBIX: 48.46 (-0.27), KMPH: 4.69 (+0.38), ZGNX: 9.83 (+0.16), PFE: 34.91 (-0.20), AZN: 33.58 (+0.14), TEVA: 53.78 (-0.76), ITCI: 41.11 (+0.10), OMER: 11.31 (-0.20)
Migraine Therapeutic Development Pipeline Review, H2 2015
M2 - Thu Jan 28, 4:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/tw7v3m/migraine) has announced the addition of the "Migraine - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Migraine, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Migraine and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Migraine Overview - Therapeutics Development - Pipeline Products for Migraine - Overview - Pipeline Products for Migraine - Comparative Analysis - Migraine - Therapeutics under Development by Companies - Migraine - Therapeutics under Investigation by Universities/Institutes - Migraine - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Migraine - Products under Development by Companies - Migraine - Products under Investigation by Universities/Institutes - Migraine - Companies Involved in Therapeutics Development - Ache Laboratorios Farmaceuticos S/A - Acorda Therapeutics, Inc. - Afferent Pharmaceuticals, Inc. - Alder Biopharmaceuticals Inc. - Allergan Plc - Amgen Inc. - Astellas Pharma Inc. - BioDelivery Sciences International, Inc. - Biofrontera AG - Charleston Laboratories, Inc. - CoLucid Pharmaceuticals, Inc. - Corium International, Inc. - D-Pharm Ltd. - Eli Lilly and Company - iCeutica, Inc. - Impel NeuroPharma, Inc. - Mallinckrodt Plc - Medestea Research & Production S.p.A. - Merck & Co., Inc. - Monosol Rx, LLC - NAL Pharmaceuticals Ltd. - Nektar Therapeutics - Noxxon Pharma AG - Otsuka Holdings Co., Ltd. - Pantarhei Bioscience BV - Pivot Pharmaceuticals Inc - Pozen, Inc. - Promius Pharma, LLC - RedHill Biopharma Ltd. - Revance Therapeutics, Inc. - Shin Nippon Biomedical Laboratories, Ltd. - Suda Ltd - Teva Pharmaceutical Industries Limited - TheraJect, Inc. - Trevena, Inc. - Trigemina, Inc. - Vertex Pharmaceuticals Incorporated - Zosano Pharma Corporation For more information visit http://www.researchandmarkets.com/research/tw7v3m/migraine
BDSI: 2.84 (-0.04), TRVN: 7.35 (+0.04), VRTX: 100.03 (-2.45), RDHL: 15.35 (-0.02), ZSAN: 1.32 (unch), AMGN: 172.50 (-2.08), LLY: 80.02 (-0.24), ACOR: 24.06 (-0.20), NKTR: 17.56 (-0.08), AGN: 253.93 (-0.12), CORI: 4.43 (+0.03), ALDR: 30.44 (-0.80), CLCD: 8.75 (-0.02), MRK: 63.01 (-0.31), TEVA: 53.78 (-0.76), RVNC: 15.50 (+0.50), POZN: 5.94 (-0.43)
Traders Look to Upside - Analyst Research on Nintendo, Experian, Otsuka Holdings and Terna Rete Elettrica Nazionale
ACCESSWIRE - Fri Jan 22, 8:10AM CST
NEW YORK, NY / ACCESSWIRE / January 22, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Nintendo Co. Ltd. (OTC: NTDOY), Experian PLC (OTC: EXPGY), Otsuka Holdings Co. Ltd. (OTC: OTSKY) and Terna Rete Elettrica Nazionale SPA (OTC: TEZNY). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2015
M2 - Thu Jan 14, 5:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/z9cx7q/chronic_kidney) has announced the addition of the "Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2015" report to their offering. The report Chronic Kidney Disease (Chronic Renal Failure) provides an overview of its therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic Kidney Disease (Chronic Renal Failure) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic Kidney Disease (Chronic Renal Failure) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Acceleron Pharma, Inc. - Angion Biomedica Corp. - Apceth GmbH & Co. KG - Astellas Pharma Inc. - Bayer AG - Bio-inRen - Boryung Pharmaceutical Co., Ltd. - Complexa, Inc. - Eli Lilly and Company - Evotec AG - Intercept Pharmaceuticals, Inc. - Isis Pharmaceuticals, Inc. - La Jolla Pharmaceutical Company - Lupin Limited - Nippon Zoki Pharmaceutical Co., Ltd. - OPKO Health, Inc. - Otsuka Holdings Co., Ltd. - Prismic Pharmaceuticals, Inc. - Prolong Pharmaceuticals - ProMetic Life Sciences Inc. - Reata Pharmaceuticals, Inc. - Red Glead Discovery AB - RegenMedTX, LLC - Resverlogix Corp. - Sphaera Pharma Pvt. Ltd. - Stelic Institute & Co. - Thrasos Therapeutics Inc. - Toray Industries, Inc. - VBS Pharmaceuticals - Vicore Pharma AB For more information visit http://www.researchandmarkets.com/research/z9...nic_kidney
LLY: 80.02 (-0.24), ISIS: 57.56 (-0.28), OPK: 10.04 (-0.04), ICPT: 165.48 (+0.43), XLRN: 30.00 (-0.15)
Global Treatment Resistant Depression Therapeutics Pipeline Review, H2 2015
M2 - Wed Jan 06, 8:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/qczdjq/treatment) has announced the addition of the "Treatment Resistant Depression - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Treatment Resistant Depression, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Treatment Resistant Depression and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Report Coverage - Treatment Resistant Depression Overview - Therapeutics Development - Pipeline Products for Treatment Resistant Depression - Overview - Pipeline Products for Treatment Resistant Depression - Comparative Analysis - Treatment Resistant Depression - Therapeutics under Development by Companies - Treatment Resistant Depression - Therapeutics under Investigation by Universities/Institutes - Treatment Resistant Depression - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Treatment Resistant Depression - Products under Development by Companies - Treatment Resistant Depression - Products under Investigation by Universities/Institutes - Treatment Resistant Depression - Companies Involved in Therapeutics Development - Addex Therapeutics Ltd - Amorsa Therapeutics Inc. - F. Hoffmann-La Roche Ltd. - Johnson & Johnson - Otsuka Holdings Co., Ltd. For more information visit http://www.researchandmarkets.com/research/qczdjq/treatment
JNJ: 120.47 (-1.84)
Nocturia Global Clinical Trials Review, H2, 2015 - Analysis, Technologies & Forecasts
M2 - Tue Dec 29, 11:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/q32p5v/nocturia_global) has announced the addition of the "Nocturia Global Clinical Trials Review, H2, 2015" report to their offering. The clinical trial report, Nocturia Global Clinical Trials Review, H2, 2015" provides an overview of Nocturia clinical trials scenario. This report provides top line data relating to the clinical trials on Nocturia. The eport includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. It also provides prominent drugs for in-progress trials (based on number of ongoing trials). Key Topics Covered: - The report provides a snapshot of the global clinical trials landscape - Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status - The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company - The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment - The Report provides enrollment trends for the past five years - Report provides latest news for the past three months Benefits of this Report: - Assists in formulating key business strategies with regards to investment - Helps in identifying prominent locations for conducting clinical trials which saves time and cost - Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities - Supports understanding of trials count and enrollment trends by country in global therapeutics market - Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials - Facilitates clinical trial assessment of the indication on a global, regional and country level Companies Mentioned: - Ferring International Center S.A. - Vantia Limited - Serenity Pharmaceuticals Corporation - OBN (UK) Ltd. - Accelovance Inc. - Astellas Pharma Inc. - Allergan Plc - Otsuka Holdings Co., Ltd. - Axis Clinical Trials For more information visit http://www.researchandmarkets.com/research/q3...ria_global
AGN: 253.93 (-0.12)
Polycystic Kidney Disease Global Clinical Trials Review, H2, 2015 - Analysis, Technologies & Forecasts
M2 - Tue Dec 29, 8:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/lj4h24/polycystic_kidney) has announced the addition of the "Polycystic Kidney Disease Global Clinical Trials Review, H2, 2015" report to their offering. The clinical trial report, Polycystic Kidney Disease Global Clinical Trials Review, H2, 2015" provides an overview of Polycystic Kidney Disease clinical trials scenario. This report provides top line data relating to the clinical trials on Polycystic Kidney Disease. The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. It also provides prominent drugs for in-progress trials (based on number of ongoing trials). Key Topics Covered: - The report provides a snapshot of the global clinical trials landscape - Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status - The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company - The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment Benefits of this Report: - Assists in formulating key business strategies with regards to investment - Helps in identifying prominent locations for conducting clinical trials which saves time and cost - Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities - Supports understanding of trials count and enrollment trends by country in global therapeutics market - Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials - Facilitates clinical trial assessment of the indication on a global, regional and country level Companies Mentioned: - Otsuka Holdings Co., Ltd. - Pfizer Inc. - Ipsen S.A. - Novartis AG - Kadmon Corporation, LLC - Merck & Co., Inc. - Daiichi Sankyo Company, Limited - Diablo Clinical Research, Inc. - C. H. Boehringer Sohn AG & Co. KG - Boehringer Ingelheim Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/lj...tic_kidney
PFE: 34.91 (-0.20), MRK: 63.01 (-0.31), NVS: 81.90 (-0.44)
Major Depressive Disorder - Pipeline Review, H2 2015
M2 - Thu Dec 17, 2:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/496zq2/major_depressive) has announced the addition of the "Major Depressive Disorder - Pipeline Review, H2 2015" report to their offering. The report provides an overview of the Major Depressive Disorder's therapeutic pipeline. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to Buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Major Depressive Disorder - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Major Depressive Disorder pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Aequus Pharmaceuticals Inc. - Alkermes Plc - Allergan Plc - Angelini Group - Azevan Pharmaceuticals, Inc. - BioCrea GmbH - Bristol-Myers Squibb Company - Cerecor Inc. - e-Therapeutics Plc - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - H. Lundbeck A/S - Hua Medicine Ltd. - Intra-Cellular Therapies, Inc. - Jiangsu Hansoh Pharmaceutical Co., Ltd. - Johnson & Johnson - Lead Discovery Center GmbH - Luye Pharma Group Ltd. - Mapreg S.A.S. - Methylation Sciences Inc. - miCure Therapeutics Ltd. - Mitsubishi Tanabe Pharma Corporation - Naurex, Inc. - Neuralstem, Inc. - nLife Therapeutics, S.L. - Otsuka Holdings Co., Ltd. - Pherin Pharmaceuticals, Inc. - Reviva Pharmaceuticals Inc. - Richter Gedeon Nyrt. - Saniona AB - Sumitomo Dainippon Pharma Co., Ltd. - Sunovion Pharmaceuticals Inc. - Suven Life Sciences Ltd. - VistaGen Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/49...depressive
LLY: 80.02 (-0.24), BMY: 59.54 (-0.49), GSK: 44.38 (-0.02), ALKS: 47.03 (-1.00), AGN: 253.93 (-0.12), CERCU: 5.03 (-0.56), JNJ: 120.47 (-1.84), ITCI: 41.11 (+0.10), CUR: 0.27 (+0.06)
Global Refractory Acute Myeloid Leukemia Therapeutics Pipeline Review, H2 2015 - 50 Companies & 117 Drug Profiles
M2 - Mon Dec 14, 10:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/5gtx2j/refractory_acute) has announced the addition of the "Refractory Acute Myeloid Leukemia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Refractory Acute Myeloid Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Acute Myeloid Leukemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 4SC AG - AbbVie Inc. - Actinium Pharmaceuticals, Inc. - Agios Pharmaceuticals, Inc. - Amgen Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - BioLineRx, Ltd. - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - Calithera Biosciences, Inc. - Celgene Corporation - Cornerstone Pharmaceuticals, Inc. - CTI BioPharma Corp. - Daiichi Sankyo Company, Limited - Eisai Co., Ltd. - EpiZyme, Inc. - GlaxoSmithKline Plc - Jiangsu Hansoh Pharmaceutical Co., Ltd. - JW Pharmaceutical Corporation - Karyopharm Therapeutics, Inc. - Kyowa Hakko Kirin Co., Ltd. - Les Laboratoires Servier SAS - MacroGenics, Inc. - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - NantKwest, Inc. - Novartis AG - Otsuka Holdings Co., Ltd. - Oxford BioTherapeutics Ltd - Synta Pharmaceuticals Corp. - TaiGen Biotechnology Co., Ltd. - Threshold Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/5g...tory_acute
MGNX: 31.93 (+0.10), AMGN: 172.50 (-2.08), EPZM: 8.63 (-0.09), GSK: 44.38 (-0.02), BMY: 59.54 (-0.49), CTIC: 0.35 (unch), SNTA: 0.34 (+0.07), ATNM: 1.70 (-0.02), MRK: 63.01 (-0.31), AZN: 33.58 (+0.14), AVEO: 0.97 (-0.03), CALA: 3.12 (-0.16), ABBV: 66.83 (-0.56), AGIO: 41.30 (-0.33), NVS: 81.90 (-0.44), KPTI: 7.26 (+0.04), CELGZ: 1.23 (+0.01)
World Adenocarcinoma of the Gastroesophageal Junction Pipeline Review, H2 2015 - 28 Companies & 32 Drug Profiles
M2 - Mon Dec 14, 9:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/x93qtv/adenocarcinoma_of) has announced the addition of the "Adenocarcinoma of the Gastroesophageal Junction - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Adenocarcinoma Of The Gastroesophageal Junction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Adenocarcinoma Of The Gastroesophageal Junction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AB Science SA - Amgen Inc. - ArQule, Inc. - AstraZeneca Plc - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - Cerulean Pharma, Inc. - Daiichi Sankyo Company, Limited - Dr. Reddy's Laboratories Limited - Eli Lilly and Company - Epirus Biopharmaceuticals, Inc. - F. Hoffmann-La Roche Ltd. - Ganymed Pharmaceuticals AG - Genentech, Inc. - Gilead Sciences, Inc. - Imugene Limited - Johnson & Johnson - Mebiopharm Co., Ltd. - MedImmune, LLC - Merck & Co., Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. - Novartis AG - Oncobiologics, Inc. - Otsuka Holdings Co., Ltd. - Panacea Biotec Limited - Sanofi Drug Profiles - (tipiracil hydrochloride trifluridine) - alpelisib - AMG-337 - avelumab - AZD-4547 - BI-853520 - cabazitaxel - CRLX-101 - DS-8201a - durvalumab tremelimumab - emibetuzumab - erismodegib - GS-5745 - Her-VAXX - IMAB-362 - indusatumab vedotin - ipatasertib - ipilimumab - JNJ-42756493 - masitinib - MBP-426 - napabucasin - panitumumab - PDR-001 - pembrolizumab - pertuzumab - ramucirumab - SAR-408701 - solitomab - tivantinib - trastuzumab biosimilar - trastuzumab emtansine For more information visit http://www.researchandmarkets.com/research/x9...rcinoma_of
CERU: 2.86 (-0.02), ARQL: 1.45 (-0.05), AMGN: 172.50 (-2.08), LLY: 80.02 (-0.24), BMY: 59.54 (-0.49), JNJ: 120.47 (-1.84), GILD: 79.56 (-0.09), MRK: 63.01 (-0.31), AZN: 33.58 (+0.14), NVS: 81.90 (-0.44)
Mycobacterium Tuberculosis Infections Global Clinical Trials Review, H2, 2015 - Analysis, Technologies & Forecast
M2 - Mon Dec 14, 5:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/zcz4kq/mycobacterium) has announced the addition of the "Mycobacterium Tuberculosis Infections Global Clinical Trials Review, H2, 2015" report to their offering. The clinical trial report, Mycobacterium Tuberculosis Infections Global Clinical Trials Review, H2, 2015" provides an overview of Mycobacterium Tuberculosis Infections clinical trials scenario. This report provides top line data relating to the clinical trials on Mycobacterium Tuberculosis Infections. It includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using Our proprietary database - Pharma eTrack Clinical trials database. Key Topics Covered: - The report provides a snapshot of the global clinical trials landscape - Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status - The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company - The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment - The Report provides enrollment trends for the past five years Benefits of this Report: - Assists in formulating key business strategies with regards to investment - Helps in identifying prominent locations for conducting clinical trials which saves time and cost - Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities - Supports understanding of trials count and enrollment trends by country in global therapeutics market - Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials Companies Mentioned: - Johnson & Johnson - GlaxoSmithKline Plc - Pfizer Inc. - Sanofi - Macleods Pharmaceuticals Limited - Sequella, Inc. - Merck & Co., Inc. - Quintiles Transnational Holdings Inc. - Otsuka Holdings Co., Ltd. - Bandim Health Project For more information visit http://www.researchandmarkets.com/research/zc...obacterium
JNJ: 120.47 (-1.84), PFE: 34.91 (-0.20), MRK: 63.01 (-0.31), GSK: 44.38 (-0.02)
Dyskinesia Pipeline Review - H2 2015 Report
M2 - Thu Dec 10, 10:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/vmxv9t/dyskinesia) has announced the addition of the "Dyskinesia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Dyskinesia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dyskinesia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Adamas Pharmaceuticals, Inc. - Addex Therapeutics Ltd - Advicenne Pharma - Amarantus Bioscience Holdings, Inc. - Astraea Therapeutics, LLC - BioMarin Pharmaceutical Inc. - Catalyst Biosciences, Inc. - Catalyst Pharmaceutical Partners, Inc. - Cerecor Inc. - Contera Pharma ApS - EpiVax, Inc. - Heptares Therapeutics Limited - Hua Medicine Ltd. - Integrative Research Laboratories Sweden AB - Ipsen S.A. - Medy-Tox Inc. - Merz Pharmaceuticals GmbH - MitoDys Therapeutics Limited - Neurim Pharmaceuticals Ltd - Neurocrine Biosciences, Inc. - Neurolixis Inc. - Osmotica Pharmaceutical Corp. - Otsuka Holdings Co., Ltd. - Revance Therapeutics, Inc. - Santhera Pharmaceuticals Holding AG - SciFluor Life Sciences, LLC - Synchroneuron Inc. - Teva Pharmaceutical Industries Limited For more information visit http://www.researchandmarkets.com/research/vmxv9t/dyskinesia
CERCU: 5.03 (-0.56), NBIX: 48.46 (-0.27), BMRN: 90.97 (-2.14), CPRX: 0.76 (+0.01), CBIO: 1.34 (unch), TEVA: 53.77 (-0.77), RVNC: 15.50 (+0.50)
Dementia Therapeutics - H2 2015 Pipeline Review
M2 - Fri Dec 04, 4:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/lj5mlv/dementia) has announced the addition of the "Dementia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Dementia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dementia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Adamas Pharmaceuticals, Inc. - Addex Therapeutics Ltd - Alector LLC - AlzProtect SAS - Apceth GmbH & Co. KG - BioArctic Neuroscience AB - Biogen, Inc. - Biotie Therapies Corp. - Chase Pharmaceuticals Corporation - Chronos Therapeutics Limited - Daewoong Pharmaceutical Co., Ltd. - Eisai Co., Ltd. - FORUM Pharmaceuticals Inc. - H. Lundbeck A/S - Hyundai Pharmaceutical Co., Ltd. - Ildong Pharmaceutical Co., Ltd. - IMMD Inc. - ImStar Therapeutics Inc. - Integrative Research Laboratories Sweden AB - Intellect Neurosciences, Inc. - Intra-Cellular Therapies, Inc. - MediPost Co., Ltd. - Neurimmune Holding AG - Neurodyn Inc. - Neuropore Therapies, Inc. - Oryzon Genomics S.A. - Otsuka Holdings Co., Ltd. - Pacific Northwest Biotechnology, LLC - Pivot Pharmaceuticals Inc - ProteoTech, Inc. - Sinil Pharmaceutical Co., Ltd - SK Chemicals Co., Ltd. - Tautatis Incorporated - Varinel, Inc. - WhanIn Pharmaceutical Co., Ltd. For more information visit http://www.researchandmarkets.com/research/lj5mlv/dementia
ITCI: 41.11 (+0.10)
Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2015
M2 - Fri Dec 04, 4:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/dk2pfp/posttraumatic) has announced the addition of the "Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Post-Traumatic Stress Disorder (PTSD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post-Traumatic Stress Disorder (PTSD) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Addex Therapeutics Ltd - Azevan Pharmaceuticals, Inc. - Catalyst Pharmaceutical Partners, Inc. - Eli Lilly and Company - HolsboerMaschmeyer NeuroChemie GmbH - Humanetics Corporation - Intra-Cellular Therapies, Inc. - Marinus Pharmaceuticals, Inc. - Neuralstem, Inc. - Neurocrine Biosciences, Inc. - NeuroNascent, Inc. - Omeros Corporation - Otsuka Holdings Co., Ltd. - Pfizer Inc. - Polleo Pharma Limited - Synchroneuron Inc. - Tonix Pharmaceuticals Holding Corp. - Vanda Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/dk...ttraumatic
NBIX: 48.46 (-0.27), TNXP: 2.50 (unch), MRNS: 1.47 (-0.12), CPRX: 0.76 (+0.01), VNDA: 12.68 (unch), PFE: 34.91 (-0.20), ITCI: 41.11 (+0.10), LLY: 80.02 (-0.24), OMER: 11.31 (-0.20), CUR: 0.27 (+0.06)
